Information Provided By: 
Fly News Breaks for September 22, 2017
EXEL
Sep 22, 2017 | 08:00 EDT
SunTrust analyst Peter Lawson says that the trial of Exelixis' cabozantinib.in liver cancer will most likely be continued through 2018. He views this scenario as "neutral to negative" for the stock. However, he recommends buying the shares on any weakness, citing what he sees as upcoming positive catalysts, including opportunities in bladder, breast and lung, new data, "and potential revenue beats from broadening use and 1H18 label expansion." He keeps a $33 price target and a Buy rating on the shares.
News For EXEL From the Last 2 Days
There are no results for your query EXEL
